Research progress on different regulatory mechanisms of triple-negative breast cancer
10.3760/cma.j.cn.115807-20200921-00288
- VernacularTitle:三阴性乳腺癌细胞生长增殖的不同调节机制研究进展
- Author:
Yanan HUANG
1
;
Jiaping QIN
;
Qiang LIU
;
Jian FU
Author Information
1. 海南医学院药理学教研室，海南 571199
- Keywords:
Triple negative breast cancer;
PI3K/AKT/mTOR pathway;
lncRNA;
miRNA;
Proliferation and apoptosis
- From:
Chinese Journal of Endocrine Surgery
2023;17(5):635-637
- CountryChina
- Language:Chinese
-
Abstract:
According to different biological functions, breast cancer can be divided into triple-negative breast cancer and non-triple-negative breast cancer. The former has stronger proliferation and invasion ability and faster metastasis. Its immune tissue indicators are estrogen receptor (estrogen receptor, ER) and progesterone receptor. Both the body (progesterone receptor,PR) and human epidermal growth factor 2 receptor (human epidermal growthFactor receptor, HER2) are negative. Surgery and radiotherapy are traditional therapies for TNBC, but these therapies have many side effects and poor prognosis. In order to better prevent the spread and treatment of TNBC, it is particularly important to study the growth, proliferation and apoptosis mechanisms of cancer cells. In recent years, studies have shown that a variety of signaling pathways, lncRNA, and miRNA all affect the growth process of TNBC. In recent years, studies have shown that a variety of signaling pathways, lncRNA, and miRNA all affect the growth process of TNBC. This article reviews domestic and foreign studies on the relevant regulatory mechanisms of TNBC cell proliferation and apoptosis, aiming to clarify the importance of breast cancer cell proliferation and apoptosis pathways, and provide new ideas for drug development for TNBC targeted therapy.
